Multiple myeloma, a cancer of the bone marrow, often recurs after initial therapy. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called AT7519M in patients with multiple myeloma that persists or has returned despite at least two previous regimens of chemotherapy.
AT7519M works by inhibiting enzymes that multiple myeloma cells need to grow and multiply. It will be evaluated alone and in combination with bortezomib, a drug that is already routinely used to treat multiple myeloma. AT7519M is given intravenously (by vein).